QoL impact on new cancer treatment adoption

A global pharmaceutical company was considering the launch of a new Fixed-Dose Combination (FDC) indication for 2 products currently existing in the Metastatic Breast Care space.

In the absence of therapeutic innovation, the client needed to understand potential reactions to the FDC and to uncover emotional drivers which they might leverage to motivate adoption.

Following the research, the client was armed with a clearer idea of the risks and potential successes of launching the FDC and the importance of leveraging the emotional connection that HCP’s have with this patient type.  They were provided with a strategic plan on how best to launch the FDC, including patient pull strategies, and an HCP plan which includes oncologists, nurses, pharmacists, and P & T committees.